Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Hashimoto's thyroiditis is named after Dr Hakaru Hashimoto, who first described the condition in 1912. It is part of the spectrum of autoimmune disease and the most common cause of goitrous hypothyroidism in non-iodine-deficient areas. However, there is also an atrophic form of autoimmune thyroiditis (Ord's thyroiditis) which is more common in Europe.
In this condition, typically there is aggressive destruction of thyroid cells by various cell- and antibody-mediated immune processes (in contrast to the stimulatory effect seen in Graves' disease). It is not yet understood why this occurs. The major environmental triggers of autoimmune thyroid disease include iodine, medications, infection, smoking and diet. Patients' iron levels (particularly in menstruating women), vitamin D status and selenium intake (in areas of iodine deficiency/excess) are important.
- Antibodies binding to and blocking the thyroid-stimulating hormone (TSH) receptor have been described and may contribute to further impairment in thyroid function.
- The result is inadequate thyroid hormone production and secretion, although, initially both preformed thyroxine (T4) and triiodothyronine (T3) may 'leak' into the circulation from damaged cells.
- The goitrous form (rather than atrophic) is associated with HLA-DR5.
- Twin studies indicate that there is about 70% genetic contribution to autoimmune thyroid disease.
- In Caucasians it is estimated at approximately 5%. The dysfunction of the gland may be clinically evident (0.1-2% of the population) or subclinical (10-15%). The pathology is diagnosed five to ten times more often in women than men and its incidence increases with the age (the peak of the number of cases is between 45 and 65); however, it can also be diagnosed in children.
- The disease is 15-20 times as frequent in women as in men.
- It occurs especially during the decades from ages 30 to 50, but may be seen in any age group, including children.
- In children, the most common age at presentation is adolescence but the disease may occur at any time, rarely even in children under 1 year of age.
- The thyroid gland may enlarge rapidly:
- Occasionally it is associated with dyspnoea or dysphagia from pressure on structures in the neck, or with mild pain and tenderness.
- Rarely, pain is persistent and unresponsive to analgesics and requires medical therapy or surgery.
- The goitre of Hashimoto's thyroiditis may remain unchanged for decades but usually it gradually increases in size.
- Occasionally the course is marked by symptoms of mild thyrotoxicosis, especially during the early phase of the disease.
- Symptoms and signs of hypothyroidism may be present when first seen, or commonly develop over a period of several years. These may include:
- Eventually, thyroid atrophy and myxoedema may occur.
Hashimoto's thyroiditis is based on clinical findings in combination with histological appearance. The thyroid gland shows diffuse lymphocytic and plasma cell infiltration with formation of lymphoid follicles from follicular hyperplasia and damage to the follicular basement membrane. Atrophy of the thyroid parenchyma is usually evident. Thyroid autoantibodies may also be seen.
- TSH levels; this is a sensitive test of thyroid function. Levels are usually raised in hypothyroidism due to Hashimoto's thyroiditis (but also in primary hypothyroidism of any cause).
- Thyroid autoantibodies - anti-thyroid peroxidase (anti-TPO) and also anti-thyroglobulin (anti-Tg) antibodies.
- Thyroid ultrasound - usually not necessary in diagnosing Hashimoto's thyroiditis but it is useful in assessing thyroid size, echotexture and, most importantly, the presence of thyroid nodules.
- Radioactive iodine uptake and scan are used to classify a nodule as hot or cold. A cold thyroid nodule would indicate a higher risk for malignancy and would need a fine-needle aspiration biopsy.
Other studies are only performed to evaluate complications of primary hypothyroidism when indicated - eg, dyslipidaemia.
Hashimoto's thyroiditis and hypothyroidism are associated with other autoimmune conditions:
- Addison's disease.
- Diabetes mellitus.
- Pernicious anaemia.
- Alopecia areata, totalis and universalis.
- Chronic active hepatitis .
- Polymyalgia rheumatica and giant cell arteritis.
- Primary biliary cirrhosis.
- Rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus.
- Systemic sclerosis (scleroderma).
Chronic inflammation, leading to neoplastic transformation, is a well-established clinical phenomenon. Hashimoto's thyroiditis carries a significantly increased risk of papillary thyroid cancer.
- Thyroid hormone replacement - orally administered levothyroxine sodium, usually for life.
- The dose should be titrated to the individual patient's needs. The aim is to restore a clinically and biochemically euthyroid state.
- Patients who are older than 50 years (and younger patients with cardiac disease) should be started on a low dose of 25 micrograms (0.025 mg) per day. Their clinical and biochemical state is then re-examined after 6-8 weeks.
Indications for surgery include:
- A large goitre with obstructive symptoms - eg, dysphagia or stridor.
- Presence of a malignant nodule.
- Presence of a lymphoma diagnosed on fine-needle aspiration.
- Cosmetic reasons for unsightly, large goitres.
- Over-replacement with thyroxine, causing accelerated bone loss or increased heart rate.
- Hyperlipidaemia and consequences, if untreated.
- Hashimoto's encephalopathy.
- Myxoedema coma (due to extreme hypothyroidism). Untreated, this has a poor prognosis and a high mortality rate (around 30%).
With early diagnosis and levothyroxine replacement therapy, the prognosis is excellent and patients may achieve normal thyroid levels. However, normal levels do not always equate with normal functioning.
Further reading and references
Hashimoto Thyroiditis; Online Mendelian Inheritance in Man (OMIM)
McLachlan SM, Rapoport B; Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev. 2014 Feb35(1):59-105. doi: 10.1210/er.2013-1055. Epub 2013 Dec 4.
Hiromatsu Y, Satoh H, Amino N; Hashimoto's thyroiditis: history and future outlook. Hormones (Athens). 2013 Jan-Mar12(1):12-8.
Hu S, Rayman MP; Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis. Thyroid. 2017 May27(5):597-610. doi: 10.1089/thy.2016.0635. Epub 2017 Apr 6.
Effraimidis G, Wiersinga WM; Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol. 2014 Jun170(6):R241-52. doi: 10.1530/EJE-14-0047. Epub 2014 Mar 7.
Pyzik A, Grywalska E, Matyjaszek-Matuszek B, et al; Immune disorders in Hashimoto's thyroiditis: what do we know so far? J Immunol Res. 20152015:979167. doi: 10.1155/2015/979167. Epub 2015 Apr 27.
Mincer DL, Jialal I; Hashimoto Thyroiditis. 2020.
Brown RS; Autoimmune thyroiditis in childhood. J Clin Res Pediatr Endocrinol. 20135 Suppl 1:45-9. doi: 10.4274/jcrpe.855. Epub 2012 Nov 15.
Gaitonde DY, Rowley KD, Sweeney LB; Hypothyroidism: an update. Am Fam Physician. 2012 Aug 186(3):244-51.
Uhliarova B, Hajtman A; Hashimoto's thyroiditis - an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol. 2018 Nov - Dec84(6):729-735. doi: 10.1016/j.bjorl.2017.08.012. Epub 2017 Sep 14.
Hypothyroidism; NICE CKS, June 2018 (UK access only)
Ogbebor O, Patel K; Hashimoto's encephalopathy: a rare cause of delirium. BMJ Case Rep. 2019 Sep 612(9). pii: 12/9/e230118. doi: 10.1136/bcr-2019-230118.
Ylli D, Klubo-Gwiezdzinska J, Wartofsky L; Thyroid emergencies. Pol Arch Intern Med. 2019 Aug 29129(7-8):526-534. doi: 10.20452/pamw.14876. Epub 2019 Jun 25.